Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Zopiclone
Drug ID BADD_D02397
Description Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Indications and Usage For the short-term treatment of insomnia.
Marketing Status approved
ATC Code N05CF01
DrugBank ID DB01198
KEGG ID D01372
MeSH ID C515050
PubChem ID 5735
TTD Drug ID D0ZB7K
NDC Product Code 66639-265; 64330-058; 63190-0030; 65372-1185
UNII 03A5ORL08Q
Synonyms zopiclone | 6-(5-chloro-2-pyridyl)-6,7-dihydro- 7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1- piperazinecarboxylate | Zop | Zopicalma | zopiclodura | Zopiclon AbZ | Zopiclon AL | Zopiclon AZU | Zopiclon beta | Zopiclon Stada | Zopiclon TAD | zopiclon von ct | Zopiclon-neuraxpharm | Zopiclon-TEVA | Zopitan | Zorclone | Imovane | Ximovan | Zimovane | Limovan | Nu-Zopiclone | Optidorm | ratio-Zopiclone | Zopiclon-ratiopharm | Rhovane | RP 27 267 | Siaten | Somnosan | Zileze | Zimoclone | Zopi-Puren | Zopicalm
Chemical Information
Molecular Formula C17H17ClN6O3
CAS Registry Number 43200-80-2
SMILES CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Major depression19.15.01.003--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.012--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Libido disorder19.08.03.004; 21.03.02.006--Not Available
Therapeutic reaction time decreased08.06.01.015--Not Available
Abnormal behaviour19.01.01.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Disease progression08.01.03.038--
Drug intolerance08.06.01.013--Not Available
Poor quality sleep17.15.04.002; 19.02.05.005--Not Available
Uterine mass21.07.01.012--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Abdominal mass07.01.01.003--Not Available
Ovarian cancer metastatic21.11.01.013; 16.12.04.004--Not Available
Ovarian mass21.11.02.017--Not Available
Cancer fatigue16.32.03.035; 08.01.01.015--Not Available
Chest wall cyst16.18.01.012; 15.09.01.012--Not Available
Discoloured vomit07.01.07.017--Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Taste disorder07.14.03.004; 17.02.07.029--Not Available
Therapeutic product effect decreased08.06.01.050--Not Available
Therapeutic product ineffective08.06.01.057--Not Available
Therapeutic response changed08.06.01.059--Not Available
The 6th Page    First    Pre   6    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene